• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Calyxo Expands Board of Directors as Number of Patients Treated with its CVAC® System Crosses 20,000 Milestone

    10/8/25 8:00:00 AM ET
    $HTFL
    $INSP
    $LUNG
    $NARI
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $HTFL alert in real time by email

    -- Dana G. Mead, Jr. brings 30 years of expertise in product strategy, development and commercialization to the Calyxo boardroom, as the company marks its next stage of growth.

    -- More than 20,000 patients have been treated with the CVAC System, underscoring the increasing adoption of the SURE procedure and its impact in kidney stone care.

    Calyxo, Inc., a medical device company advancing innovative solutions for kidney stone treatment, marked key milestones as adoption of the steerable ureteroscopic renal evacuation (SURE) procedure using the company's CVAC System continues to accelerate. The company has appointed Dana G. Mead, Jr. to its board of directors, and it has reached more than 20,000 patients treated to date with the CVAC System, further establishing the technology as a new standard in kidney stone care.

    Mead brings four decades of medical device operating and investing experience to the Calyxo Board. He currently serves on the Board of Directors of Inspire Medical Systems (NYSE:INSP), Pulmonx (NASDAQ:LUNG), and several commercial-stage private companies. He was a board member of Intersect ENT (NASDAQ:ENT) prior to its acquisition by Medtronic in 2021, and of Inari Medical (NASDAQ:NARI) prior to Stryker's acquisition of the company earlier this year. Other past board appointments include Teladoc Health (NYSE:TDOC). From 2019 to 2021, he was President and CEO of HeartFlow (NASDAQ:HTFL). From 2016 to 2019, he was President and CEO of BVI. Prior to that, he was a Life Science Partner at Kleiner Perkins Caufield & Byers, a leading venture capital firm, and served in a series of general management roles of increasing responsibility at Guidant.

    "Calyxo is at an exciting inflection point. The company's rapid growth reflects strong physician confidence and a clear need for innovation in kidney stone care. I'm inspired by the team's commitment to advancing patient outcomes and look forward to helping guide this next chapter of growth as the company continues to scale," said Mead.

    "Dana will be an asset to our board. We value his extensive and broad experience across public and private medtech companies of all sizes as we continue to experience positive momentum and growing adoption of the CVAC System," said Joe Catanese, CEO of Calyxo. "Reaching the significant milestone of 20,000 patients treated shows that more physicians are embracing the SURE procedure with the CVAC System, which is designed to achieve greater kidney stone clearance, and marks an important inflection point in Calyxo's growth story."

    Data presented last month at the 42nd World Congress of Endourology and Uro-Technology (WCET) in Phoenix, Ariz. showed the second-generation CVAC System is safe and effective at removing stones, with a mean stone clearance from 94-96%.1 Two-year data from the landmark ASPIRE study showed treatment with SURE using the company's CVAC System resulted in 73% fewer healthcare consumption events (such as emergency room visits, hospitalizations or retreatment*) compared to standard ureteroscopy (URS).2 The study demonstrated residual stone volume was the only significant predictor of post-procedure healthcare consumption events, besides age. This growing body of evidence supporting the safety and effectiveness of the CVAC System is encouraging more urologists to adopt the technology in their practices.

    "The SURE procedure using the second-generation CVAC System has changed the way I care for patients with kidney stones. Now I can achieve greater stone clearance with fewer complications and follow-up interventions. For patients with moderate to large stone burden, the SURE procedure can achieve this less invasively than other procedures. For patients, that means faster recoveries, fewer emergency department visits, less need for a repeat procedure, and less invasive surgical techniques," said Michelle Jo Semins, MD of West Virginia University Medicine. "The CVAC System has become an invaluable part of my treatment approach. Calyxo's commitment to innovation gives physicians like me the confidence that we are providing the best possible care today -- and helping define where kidney stone treatment is headed. This is one of the biggest advancements in surgical stone treatment in decades."

    References:

    1. Eisner et al. MP16: 17 Prospective Evaluation of Steerable Ureteroscopic Renal Evacuation with the Second-Generation CVAC® Aspiration System: Findings from the CLEARANCE Study. Conference Presentation, WCET 2025.

    2. Stern et al. MP16: 01 Steerable ureteroscopic renal evacuation reduces the risk of healthcare consumption events at 2 years compared to standard ureteroscopy (URS). Conference Presentation, WCET 2025.

    * Limited to retreatments likely due to residual stones at the end of the procedure.

    About Kidney Stones

    According to the American Urological Association, approximately 10% of people in the U.S. will have a kidney stone at some point in their lives. Kidney stone disease is a painful condition that can result in significant healthcare costs (Current Urology Reports estimates $4.1 billion in annual direct treatment costs by 2030).

    About the CVAC System

    The CVAC System was FDA-cleared in 2024 and enables a minimally invasive approach for kidney stone clearance. It is an all-in-one solution designed to efficiently and effectively remove kidney stones. It uses irrigation and vacuum aspiration to continuously clear stone fragments during and after laser lithotripsy, enabling physicians to achieve a stone-free outcome.

    About Calyxo, Inc.

    Calyxo, Inc. is an innovation-driven medical device company focused on improving care for patients with kidney stones by delivering paradigm-shifting solutions that enable urologists to safely, effectively and efficiently achieve unrivaled clinical outcomes. Learn more at calyxoinc.com.

    "CVAC" and "Calyxo" are registered trademarks of Calyxo, Inc.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251008062288/en/

    Alyssa Paldo

    [email protected]

    M: +1 847 791 8085

    Get the next $HTFL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HTFL
    $INSP
    $LUNG
    $NARI

    CompanyDatePrice TargetRatingAnalyst
    Inspire Medical Systems Inc.
    $INSP
    10/24/2025$85.00Buy → Hold
    Jefferies
    Inspire Medical Systems Inc.
    $INSP
    9/22/2025$89.00Buy → Neutral
    UBS
    Inspire Medical Systems Inc.
    $INSP
    9/2/2025$150.00Outperform
    Evercore ISI
    Heartflow Inc.
    $HTFL
    9/2/2025$36.00Overweight
    Analyst
    Heartflow Inc.
    $HTFL
    9/2/2025$38.00Overweight
    Piper Sandler
    Heartflow Inc.
    $HTFL
    9/2/2025$35.00Buy
    Stifel
    Heartflow Inc.
    $HTFL
    9/2/2025$35.00Buy
    Canaccord Genuity
    Heartflow Inc.
    $HTFL
    9/2/2025$35.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $HTFL
    $INSP
    $LUNG
    $NARI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 21, 2023 - FDA Roundup: March 21, 2023

    For Immediate Release: March 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA completed its second pre-market consultation for a human food made from cultured animal cells. The firm will use animal cell culture technology to take living cells from chickens and grow the cells in a controlled environment to make the cultured

    3/21/23 3:12:46 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $HTFL
    $INSP
    $LUNG
    $NARI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Florin Daniel P bought $71,362 worth of shares (23,321 units at $3.06), increasing direct ownership by 25% to 117,231 units (SEC Form 4)

    4 - Pulmonx Corp (0001127537) (Issuer)

    6/5/25 8:39:08 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Director Mckinley Thomas bought $30,756 worth of shares (4,000 units at $7.69), increasing direct ownership by 11% to 39,077 units (SEC Form 4)

    4 - Teladoc Health, Inc. (0001477449) (Issuer)

    9/13/24 5:14:02 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    PRESIDENT AND CEO Williamson Steven S. bought $97,436 worth of shares (14,245 units at $6.84), increasing direct ownership by 7% to 219,531 units (SEC Form 4)

    4 - Pulmonx Corp (0001127537) (Issuer)

    8/22/24 6:41:17 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $HTFL
    $INSP
    $LUNG
    $NARI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AR/VR is Revolutionizing Medical Education & Training While Transforming Healthcare Industry

    NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- MarketNewsUpdates News Commentary A recent report from ResearchAndMarkets said that the U.S. augmented reality and virtual reality in healthcare market size which was estimated at USD 1.03 billion in 2024 is projected to grow at a CAGR of 15.4% from 2025 to 2030. It said that advancements in healthcare IT infrastructure and increased venture capital investment, fueled by numerous start-ups and government programs such as NIH and FDA initiatives, support AR/VR research. In addition, the declining cost of head-mounted devices, rising demand from telemedicine, chronic disease care, and minimally invasive surgery, and integration with AI and 5G tech

    10/28/25 9:00:00 AM ET
    $GPRO
    $QCOM
    $TDOC
    Industrial Machinery/Components
    Consumer Discretionary
    Radio And Television Broadcasting And Communications Equipment
    Technology

    Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025

    Glen French, member of the Board of Directors and former Pulmonx President and Chief Executive Officer, reappointed President and Chief Executive OfficerDerrick Sung, former Pulmonx Chief Financial Officer, appointed Chief Operating Officer and Chief Financial OfficerSteve Williamson and Mehul Joshi have resigned from their respective roles at the Company, effective immediatelyPreliminary, unaudited third quarter 2025 revenue expected to be approximately $21.5 millionThird quarter 2025 financial results rescheduled to be released after the close of trading on Wednesday, November 12, 2025; Management to host conference call to discuss the results and the transition at 1:30 p.m. PT / 4:30 p.m.

    10/27/25 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems, Inc. to Present at the 2025 UBS Global Healthcare Conference

    MINNEAPOLIS, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the 2025 UBS Global Healthcare Conference on Monday, November 10, 2025. Inspire is scheduled to present at 11:45 a.m. Eastern Time. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire's Investor website at https://investors.inspi

    10/27/25 8:00:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $HTFL
    $INSP
    $LUNG
    $NARI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Melenikiotou Georgia was granted 229 shares, increasing direct ownership by 6% to 3,986 units (SEC Form 4)

    4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

    10/16/25 4:16:07 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Director Tansey Casey M was granted 221 shares, increasing direct ownership by 1% to 22,235 units (SEC Form 4)

    4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

    10/16/25 4:15:47 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Director Ellis Gary Lee was granted 372 shares, increasing direct ownership by 6% to 6,454 units (SEC Form 4)

    4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

    10/16/25 4:15:28 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $HTFL
    $INSP
    $LUNG
    $NARI
    SEC Filings

    View All

    Pulmonx Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - Pulmonx Corp (0001127537) (Filer)

    10/27/25 4:05:33 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Teladoc Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Teladoc Health, Inc. (0001477449) (Filer)

    10/23/25 4:07:40 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Inspire Medical Systems Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Inspire Medical Systems, Inc. (0001609550) (Filer)

    10/10/25 6:53:17 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $HTFL
    $INSP
    $LUNG
    $NARI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Inspire Medical Systems downgraded by Jefferies with a new price target

    Jefferies downgraded Inspire Medical Systems from Buy to Hold and set a new price target of $85.00

    10/24/25 8:57:05 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems downgraded by UBS with a new price target

    UBS downgraded Inspire Medical Systems from Buy to Neutral and set a new price target of $89.00

    9/22/25 8:12:43 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Evercore ISI initiated coverage on Inspire Medical Systems with a new price target

    Evercore ISI initiated coverage of Inspire Medical Systems with a rating of Outperform and set a new price target of $150.00

    9/2/25 8:38:06 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $HTFL
    $INSP
    $LUNG
    $NARI
    Leadership Updates

    Live Leadership Updates

    View All

    AR/VR is Revolutionizing Medical Education & Training While Transforming Healthcare Industry

    NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- MarketNewsUpdates News Commentary A recent report from ResearchAndMarkets said that the U.S. augmented reality and virtual reality in healthcare market size which was estimated at USD 1.03 billion in 2024 is projected to grow at a CAGR of 15.4% from 2025 to 2030. It said that advancements in healthcare IT infrastructure and increased venture capital investment, fueled by numerous start-ups and government programs such as NIH and FDA initiatives, support AR/VR research. In addition, the declining cost of head-mounted devices, rising demand from telemedicine, chronic disease care, and minimally invasive surgery, and integration with AI and 5G tech

    10/28/25 9:00:00 AM ET
    $GPRO
    $QCOM
    $TDOC
    Industrial Machinery/Components
    Consumer Discretionary
    Radio And Television Broadcasting And Communications Equipment
    Technology

    Inspire Medical Systems, Inc. Announces the Addition of Paul T. Hoff, M.D., M.S. and Ruchir P. Patel, M.D., F.A.C.P. as Vice President, Senior Medical Directors

    MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that two leading physicians in the field of sleep medicine and sleep surgery, Paul T. Hoff, M.D., M.S., an otolaryngologist, and Ruchir P. Patel, M.D., F.A.C.P., a sleep medicine specialist, will join Inspire in Vice President, Senior Medical Director roles, effective April 21 and June 2 respectively.   "Dr. Hoff and Dr. Patel are widely regarded as experts and thought leaders in their respective fields, a

    4/21/25 8:00:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Kadant Set to Join S&P SmallCap 600

    NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Kadant Inc. (NYSE:KAI) will replace Inari Medical Inc. (NASD: NARI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 19. S&P 500 constituent Stryker Corp. (NYSE:SYK) is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name      Action Company Name Ticker GICS Sector February 19, 2025 S&P SmallCap 600 Addition Kadant KAI Industrials February 19, 2025 S&P SmallCap 600 Deletion Inari Medical NARI Health Care For more information about

    2/13/25 5:54:00 PM ET
    $KAI
    $NARI
    $SPGI
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    $HTFL
    $INSP
    $LUNG
    $NARI
    Financials

    Live finance-specific insights

    View All

    Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025

    Glen French, member of the Board of Directors and former Pulmonx President and Chief Executive Officer, reappointed President and Chief Executive OfficerDerrick Sung, former Pulmonx Chief Financial Officer, appointed Chief Operating Officer and Chief Financial OfficerSteve Williamson and Mehul Joshi have resigned from their respective roles at the Company, effective immediatelyPreliminary, unaudited third quarter 2025 revenue expected to be approximately $21.5 millionThird quarter 2025 financial results rescheduled to be released after the close of trading on Wednesday, November 12, 2025; Management to host conference call to discuss the results and the transition at 1:30 p.m. PT / 4:30 p.m.

    10/27/25 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Heartflow to Report Third Quarter 2025 Financial Results on November 12, 2025

    MOUNTAIN VIEW, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the third quarter of 2025 after market close on Wednesday, November 12, 2025. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on November 12, 2025. Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a unique PIN to join the call. Participants are encouraged to register more than 15 minutes prior to the start of t

    10/23/25 4:05:00 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Teladoc Health Announces Chief Financial Officer Transition

    NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE:TDOC), the global leader in virtual care, today announced that Mala Murthy will be stepping down from her role as Chief Financial Officer to pursue an opportunity outside of the healthcare industry. Ms. Murthy will continue to serve in her role until her departure on November 21, 2025 and will present on the company's third quarter earnings conference call. The company has initiated a search process to identify its next CFO. To ensure a seamless transition while the search is completed, an interim leadership structure will be in place with key finance leaders reporting to Teladoc Health Chief Executive Officer Chuck Divita.

    10/23/25 4:05:00 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    $HTFL
    $INSP
    $LUNG
    $NARI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

    SC 13G/A - Pulmonx Corp (0001127537) (Subject)

    11/14/24 7:47:49 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

    SC 13G/A - Pulmonx Corp (0001127537) (Subject)

    11/12/24 10:34:16 AM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Inspire Medical Systems Inc.

    SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

    11/12/24 10:32:14 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care